Efficacy of Ingenol Mebutate on Actinic Keratoses and Field Cancerization vs Cryotherapy

• Status: Completed
• Trial end date: 2018-07-30
• Target enrollment: 0
• Participant gender: All

Summary

The main objective of this study is to compare the effectiveness of ingenol mebutate gel (150 mcg / g per day, to be applied on a predetermined area of 25 cm2 of skin of the face or scalp, for 3 days consecutive) cryotherapy (application with 5 seconds of freezing time of each lesion located in a predetermined skin area of 25 cm2 of the face or scalp) in the treatment of actinic keratosis and their field cancerization.

Study details:

This study is randomized. 50 subjects with at least two actinic keratoses of grade I and II, located in two different districts of 25 cm2 skin of the face or scalp, and who meet all the inclusion criteria will be enrolled in the study by the investigators in the three different centers mentioned above.

The investigators will assess the effect of treatment by confocal microscopy and digital dermoscopy. The investigator will acquire images of selected areas of the face and scalp before and after treatment. Data will be collected and analyzed by the coordinating centre.

Procedure for the study:

Recruitment of subjects; random assignment of treatment (ingenol mebutate gel 150 micrograms/g and cryotherapy) to the two skin areas of 25 cm2 of the subject recruited; evaluation of the two areas with reflectance confocal microscopy and digital dermoscope. The measurements will be carried out at time 0, after 1 month and 6 months. The investigator must fill out a form for each subject at the beginning (day 0), after 1 month and at the end of the study (after 6 months). The subject must complete a questionnaire at the beginning (day 0), after 1 month and at the last follow-up visit (after 6 months).

Measurement parameters: Dermoscopy and confocal microscopy will be used to assess the percentage reduction in actinic keratoses and the damage of the cancerous area in the two selected areas treated with ingenol mebutate gel or cryotherapy, respectively.

Adverse / side events will be collected at each visit by the investigator and will be contained in another form.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Second University of Naples; University of Campania "Luigi Vanvitelli"

Criteria

Inclusion Criteria:

A patient will be enrolled if he/she meets all of the following inclusion criteria:

• Current diagnosis of AK, with ≥2 lesions of grade I and/or II located in two different anatomical districts (within a contiguous 25 cm2 area on the face, scalp or forehead);

• Male ≥ 18 years of age or Female > 60 years of age;

• Skin type I or II according to Fitzpatrick;

• Patient has confirmed his/her willingness to participate in this study after being informed of all aspects of the study that are relevant to his/her decision to participate, by signing and dating the approved informed consent form, according to ICH and local laws.

The 25 cm2 contiguous treatment areas could be of any shape, e.g. 5 cm x 5 cm, 2 cm x 12.5 cm, 3 cm x 8.3 cm.

Exclusion Criteria:

A patient will be excluded if he/she meets any of the following exclusion criteria:

• Has received any therapy for AK within the past 3 months

• Has AK of grade III

• Has currently a skin cancer or shows an early stage of skin cancer;

• Has another skin disease that requires treatment with other medications in the AK area or in distance of 3 cm;

• Use of cosmetic or therapeutic products and procedures which could interfere with assessments of the treatment area;

• Immunosuppressive therapies or current treatment for cancer;

• Clinically unstable medical condition;

• High risk group for HIV infection or presentation of other infectious diseases (hepatitis A virus , hepatitis B virus , hepatitis C virus , Tuberculosis, etc);

• Allergies to the tested gel (ingenol mebutate and eccipients);

• Pregnancy and breastfeeding (see inclusion criteria);

• Psychiatric disease that may interfere with follow-up of study procedures;

• Participation in other clinical trials up to 30 days prior to day 1 of the study;

• Patient is, for any reason, considered by the investigator to be an unsuitable candidate for the study.